Hospira Nabs Rights to Kiadis’ T Cell-Based GvHD-Prevention Therapy
Hospira will also partially fund ongoing registrational trials of Atir in North America and Europe.!--h2>
Hospira negotiated development and commercialization rights to Netherlands-based Kiadis Pharma’s T-cell transplantation product Atir™ in Europe, the Middle East, Africa, Australia, Japan, and parts of Asia. Under terms of the deal Kiadis retains rights to Atir in all territories not licensed to Hospira, and will receive an up-front fee along with development and commercialization milestones and future sales royalties. Hospira will partially fund the ongoing registrational trials evaluating Atir in Europe and North America.
Atir has been developed so blood cancer patients for whom no matched bone marrow donor can be found may receive hematopoietic stem cell transplantation from a mismatched family member without risk of severe acute graft-versus host disease (GvHD). The cell-based therapy comprises donor T-lymphocytes depleted of alloreactive T-cells, which is infused after a patient receives a mismatched bone marrow transplantation. Kiadis claims Atir retains useful donor immune cells that can fight infection and remaining tumor cells, and eliminates the need for immune suppressants post transplantation.